WDA
IMRX icon

Wendell David Associates’s Immuneering IMRX Stock Holding History

Wendell David Associates’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$79K Hold
15,000
– – 0.01% 150
2025
Q4 		$99K Hold
15,000
– – 0.01% 148
2025
Q3 		$105K Buy
+15,000
New +$77.8K 0.01% 148

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wendell David Associates's IMRX Position: Q1 2026 in Review

Wendell David Associates held its Immuneering (IMRX) position steady in Q1 2026 at 15,000 shares worth $79K. The position accounts for 0.01% of the portfolio, ranked #150.

Wendell David Associates first reported a position in IMRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $105K in Q3 2025. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • Wendell David Associates held 15,000 shares of Immuneering worth $79K as of Q1 2026.
  • Wendell David Associates left its Immuneering share count unchanged in Q1 2026.
  • Immuneering made up 0.01% of Wendell David Associates's portfolio in Q1 2026, its #150 holding.
  • Wendell David Associates first reported a position in Immuneering in Q3 2025 and has held it in 3 quarters since.
  • Wendell David Associates's Immuneering position peaked at $105K in Q3 2025.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Wendell David Associates's 13F filing for Q1 2026, filed 23 Apr 2026.